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Abstract
Background: Chromosome 1 open reading frame 63 (C1orf63) is located on the distal short arm of chromosome 1,
whose allelic loss has been observed in several human cancers. C1orf63 has been reported to be up-regulated in
IL-2-starved T lymphocytes, which suggests it might be involved in cell cycle control, a common mechanism for
carcinogenesis. Here we investigated the expression and clinical implication of C1orf63 in breast cancer.
Methods: Paraffin-embedded specimens, clinicopathological features and follow-up data of the breast cancer
patients were collected. Publicly available microarray and RNA-seq datasets used in this study were downloaded
from ArrayExpress of EBI and GEO of NCBI. KM plotter tool was also adopted. The expression of C1orf63 and
CDK10, one known cell cycle-dependent tumor suppressor in breast cancer, was assessed by
immunohistochemistry. Western blotting was performed to detect C1orf63 protein in human breast cancer cell
lines, purchased from the Culture Collection of the Chinese Academy of Sciences, Shanghai.
Results: In a group of 12 human breast tumors and their matched adjacent non-cancerous tissues, C1orf63
expression was observed in 7 of the 12 breast tumors, but not in the 12 adjacent non-cancerous tissues (P < 0.001).
Similar results were observed of C1orf63 mRNA expression both in breast cancer and several other cancers, including
lung cancer, prostate cancer and hepatocellular carcinoma. In another group of 182 breast cancer patients, C1orf63
expression in tumors was not correlated with any clinicopathological features collected in this study. Survival analyses
showed that there was no significant difference of overall survival (OS) rates between the C1orf63 (+) group and the
C1orf63 (−) group (P = 0.145). However, the analyses of KM plotter displayed a valid relationship between C1orf63 and
RFS (relapse free survival)/OS (P < 0.001; P = 0.007). Notablely, in breast cancers with advanced TNM stages (III ~ IV)
among these 182 patients, C1orf63 expression was an independent prognostic factor predicting better clinical
outcome (HR: 0.41; 95 % CI: 0.17 ~ 0.97; P = 0.042). Additionally, we found that CDK10 mRNA expression was positively
correlated with C1orf63, which was consistent with the relationship of protein expression between C1orf63 and CDK10
(rs = 0.391; P < 0.001).
Conclusions: Compared to adjacent non-cancerous tissues, C1orf63 expression was elevated in tumor tissues.
However, C1orf63 predicts better prognosis for breast cancers with advanced TNM stage, and the underlying
mechanism is unknown. In addition, C1orf63 is correlated with the cell cycle related gene, CDK10.
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Background
The initiation and development of breast cancer is a
multistep process encompassing progressive changes in
genetic aberrations in normal tissue, resulting in hyper-
plasia with or without atypia, in situ carcinomas, inva-
sive carcinomas, and finally metastatic carcinoma [1].
Increasing evidence reveals that molecular subtyping of
this malignancy is crucial to better understand the clin-
ical behavior of these tumors and to identify the targets
for better therapy [2, 3].
Chromosome 1 open reading frame 63 (C1orf63), also
known as arginine/serine-rich protein 1 (RSRP1, NCBI
Gene ID: 57035), is located at 1p36.13 - p35.1. Although
the function of C1orf63 is still unclear, frequent allelic
loss on the distal short arm of chromosome 1 has been
reported in a broad range of solid human tumors, in-
cluding breast, non-small cell lung and colorectal can-
cers [4]. Especially, allelic loss at 1p31.1-36.3 was shown
to be an early event in the carcinogenesis of breast can-
cer [5]. The allelic loss at 1p34-36 was demonstrated to
be an independent predictor of shorter disease-free sur-
vival for patients with node-negative breast cancer [6].
Thus, these regions on 1p may harbor tumor suppressor
genes [7]. Furthermore, it was reported that the transcrip-
tion of C1orf63 was upregulated in the interleukin (IL)-2-
dependent human T cells, which were forced to exit cell
cycle by IL-2 withdrawal, indicating that C1orf63 could be
involved in cell cycle exit and acted as a cellular
quiescence-controlling gene. Its expression might repre-
sent one early event for tumorigenesis [8]. However, the
involvement of C1or63 in the oncogenesis and progres-
sion of breast cancer has not been reported before.
In the current study, C1orf63 protein expression was
detected in breast cancer tissues, and correlated to the
clinicopathological features and prognosis of breast can-
cer. Then the relationship between C1orf63 and cyclin-
dependent kinase 10 (CDK10), a known cell cycle-
dependent tumor suppressor in breast cancer [9, 10]
was investigated. Furthermore, the potential association
between the expression of C1orf63 and known breast
cancer biomarkers including estrogen receptor (ER),
progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER-2) were also examined.
Methods
Tumor samples and cell culture
Paraffin-embedded archival pathological specimens,
complete clinicopathological features and follow-up data
were retrieved for 182 breast cancer patients (women, me-
dian age: 51 years; range: 29–88 years). The patients had
undergone curative surgery without preoperative therapy,
at the Cancer Hospital of Shantou University Medical Col-
lege, between October 2001 and November 2002. Clinical
tumor stage (TNM stage) was grouped in accordance with
the American Joint Committee on Cancer (AJCC) 6th Ed
Cancer Staging Manual (2002). In this study, stages III
and IV were designated as advanced stage, while stages I
and II were early stage [11]. The clinicopathologic features
for these patients, including expression status of ER, PR
and HER-2, were summarized in Table 1. The correspond-
ing adjacent normal tissues of 12 patients were also ob-
tained from surgical resections. The observation period
ranged from 1 to 159 months (the median period was
42 months). Informed consent for the use of their samples
was obtained from all the patients. This study was ap-
proved by the medical ethics committee of the Cancer
Hospital of Shantou University Medical College.
Four breast cancer cell lines used in this study, namely
MCF-7, MDA-MB-231, SK-BR-3 and BT549, were pur-
chased from the Culture Collection of the Chinese Acad-
emy of Sciences, Shanghai, and maintained in DMEM
(high glucose) containing 5 % fetal bovine serum.
Immunohistochemistry of breast tissues
Immunohistochemistry (IHC) for C1orf63 and CDK10
was carried out using a standard EnVision complex
method [12]. Briefly, sections (4-μm) were fixed in 10 %
buffered formalin and embedded in paraffin. After
deparaffinization and rehydration, endogenous peroxid-
ase activity was blocked with 0.3 % hydrogen peroxide
for 30 min. Then tissue sections were autoclaved at
121 °C in citrate buffer (pH 6.0) for 10 min, and incu-
bated with rabbit anti-C1orf63 polyclonal antibody
(1:100 dilution, Beijing Biosynthesis Biotechnology Co.,
Ltd., China) or CDK10 antibody (1:300 dilution, Abgent,
San Diego, USA). IHC staining was carried out by an
EnVision antibody complex (anti-mouse/rabbit) method
using an Envision™ Detection kit (ZSGB-BIO, Beijing,
China) and 3,3’-diaminobenzidine as the chromogen
substrate. A negative control was obtained by replacing
the primary antibody with normal rabbit IgG.
IHC staining for C1orf63 was scored, as described [13]
by a combination of intensity (0, no staining; 1, weak
staining; 2, moderate staining; 3, strong staining) and
proportion (0, < 5 % of tumor cells stained; 1, 5 - 25 %
positive cells; 2, 26-50 % positive cells; 3, 51 - 75 % posi-
tive cells; 4, more than 76 % positive cells). If the prod-
uct of multiplication between staining intensity and the
proportion of positive cells was > 4, expression was de-
fined as positive. Two pathologists independently
assessed the cellular location and intensity of immuno-
staining in each section.
Western blotting
Cells were lysed with a lysis buffer [50 mmol/L Tris–
HCl (pH 8.0), 150 mmol/L NaCl, 1 % Triton X-100, and
100ug/ml PMSF] on ice for 30 min and centrifuged at
12000 rpm for 15 min at 4 °C. Cell lysates (20 ug) were
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electrophoresed on 10 % SDS-polyacrylamide gel and
transferred onto a PVDF membrane. After blocking with
Tris-buffered saline containing 0.05 % Tween 20 (TBST)
and 5 % non-fat milk for 1 h at room temperature, the fil-
ters were washed 3 times/5 min with TBST and then incu-
bated with antibodies against either anti rabbit C1orf63
(1:3000) or anti mouse actin (1:6000, Santa Cruz Biotech-
nology, Santa Cruz, USA) diluted in blocking buffer for
1 h, followed by incubation with horseradish peroxidase-
labelled antirabbit (1:6000, Novus Biologicals, Littleton,
USA) or antimouse (1:6000, Santa Cruz Biotechnology)
IgG, and washed with TBST. The blots were visualized
with chemiluminescence. Human β-actin was employed
as an endogenous control.
Gene expression data
The microarray datasets employed in this study was
publicly available from ArraryExpress (http://www.ebi.ac.
uk/arrayexpress/) of EBI and GEO (http://www.ncbi.
nlm.nih.gov/gds/) of NCBI, including 6 independent co-
horts of breast cancer (accession numbers: GSE15852
[14], GSE42568 [15], GSE4922 [16], GSE5847 [17],
GSE23988 [18], E-TABM-158 [19]), 2 of lung cancer (E-
MEXP-231 [20], GSE19804 [21]), 2 of prostate cancer
(GSE6956 [22], GSE6919 [23]) and 2 of hepatocellular
carcinoma (GSE14323 [24], GSE6764 [25]). The CEL
files containing the raw data from each experiment were
directly downloaded from the websites with particular
accession number. Since RNA-seq is another popular
method for genome-wide transcriptome profiling [26],
one normalized RNA-seq dataset (GSE60788) of breast
cancer was downloaded from GEO. Details of these
datasets were summarized in Table 2 and Table 3.
In this paper, KM Plotter (http://kmplot.com/analysis/),
a tool for the meta-analysis based biomarker assessment
[27], including gene expression and survival data of more
than 4000 breast cancer patients, was used to perform
Kaplan Meier survival analysis to further assess the rela-
tionship between C1orf63 mRNA expression and RFS (re-
lapse free survival)/OS (overall survival). Breast cancer
patients were split by the median expression of C1orf63
into two groups, namely patients with high or low expres-
sion of C1orf63.
Statistical analysis
Statistical analyses were performed using software SPSS
(version 13.0) and R (version 3.0.2). The difference of
C1orf63 protein expression between tumors and adjacent
Table 1 Relationship of C1orf63 expression with clinicopathologic features and biomarkers. 182 patients with breast cancer were
included and the correlations between C1orf63 expression and clinicopathologic features were analyzed using chi-square test
Clinicopathological
features
C1orf63 expression Chisq P
Negative (≤4) n = 138 (%) Positive (>4) n = 44 (%)
Age, year
≤ 60 114 (74.5) 39 (25.5) 0.905 0.341
> 60 24 (82.8) 5 (17.2)
T (Primary tumor)
T0 ~ T2 81 (75.0) 27 (25.0) 0.183 0.669
T3 ~ T4 56 (77.8) 16 (22.2)
N (Regional lymph nodes)
N0 ~ N1 73 (78.5) 20 (21.5) 0.601 0.438
N3 ~ N4 64 (73.6) 23 (26.4)
TNM stage
I ~ II 58 (78.4) 16 (21.6) 0.315 0.575
III ~ IV 80 (74.8) 27 (25.2)
ER
Negative 55 (79.7) 14 (20.3) 1.115 0.291
Positive 80 (72.7) 30 (27.3)
PR
Negative 85 (79.4) 22 (20.6) 2.319 0.128
Positive 50 (69.4) 22 (30.6)
HER-2
Negative 82 (75.9) 26 (24.1) 0.061 0.804
Positive 52 (74.3) 18 (25.7)
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non-cancerous tissues were detected by Wilcoxon test,
and the difference of online datasets retrieved C1orf63
mRNA expression between cases and controls of several
cancer types included in this study were detected by Stu-
dent t-test. Correlations between C1orf63 expression and
clinicopathologic features were analyzed using chi-square
test. Survival curves were calculated using the Kaplan–
Meier method with log rank test. The Cox regression ana-
lysis was used to study the effects of C1orf63 expression
on OS. OS (in months) was defined as the time from diag-
nosis to the date of last contact or of death from any
cause. For gene expression microarray analyses, data were
normalized using Robust Multi-array Analysis (RMA)
with R-package “affy”. The normalized expression values
(on a log-2 scale) of probes representing the same gene
were averaged. Pearson’s correlation and Spearman’s rank
correlation were applied for examining the relationship
between C1orf63 and CDK10. P < 0.05 (two-tailed) was
considered as statistically different.
Results
C1orf63 expression in breast cancer tissues and cell lines
The tumor specimens and their matched adjacent non-
cancerous tissues were collected from a group of 12
breast cancer patients to examine C1orf63 expression by
IHC. As shown in Fig. 1A (i, ii, iii), C1orf63 protein was
expressed primarily in the cytoplasm. We found 7 of the
12 primary tumors (58.3 %) expressed C1orf63 (Table 4),
whereas 5 of the 12 tumors (41.7 %) had indistinctive ex-
pression of C1orf63. In contrast, all the adjacent normal
tissues lacked elevated C1orf63 expression (Wilcoxon
test: P < 0.001, Fig. 1A iv). Additionally, though analyzing
the publicly available datasets, upregulation of C1orf63
mRNA expression was found in cases of breast cancer
as well as other cancers, including lung cancer, prostate
cancer and hepatocellular carcinoma (Table 3 and
Fig. 1B), when compared to the relevant normal
controls.
We also performed western blotting to detect whether
C1orf63 was expressed in breast cancer cells. Four hu-
man breast cancer cell lines, including the ER+/PR+ cell
line MCF-7, ER−/PR−/Her-2− cell lines BT549 and
MDA-MB-231, and ER−/PR−/Her-2+ cell line SK-BR-3,
were examined. As shown in Fig. 2, these cells have
comparable levels of C1orf63 expression, regardless of
receptor status.
Relationship of C1orf63 with clinicopathologic features in
a cohort of 182 breast cancer patients
To evaluate the relationship of C1orf63 expression with
clinicopathological features, tumor sections from 182
primary breast cancer patients were immunostained to
detect the expression of C1orf63, and these patients
were subsequently divided into two groups according
Table 2 Five independent datasets from ArrayExpress and GEO website. Gene expression microarray datasets were normalized using
RMA with package “affy”. Pearson correlation test was applied for examining the relationship of mRNA expression between C1orf63
and CDK10
Accession number Array Sample size r P
GSE4922 HG-U133A 249 0.292 2.86 × 10−6
GSE5847 HG-U133A 95 0.304 3.00 × 10−3
GSE23988 HG-U133A 61 0.327 1.00 × 10−2
E-TABM-158 U133AAofAv2 130 0.324 1.68 × 10−4
GSE60788 Illumina HiSeq 2000 55 0.521 4.57 × 10−5
Table 3 Eight independent datasets from ArrayExpress and GEO website. Gene expression microarray datasets were normalized
using RMA with package “affy”. Student t-test was performed for examining the differential expression of C1orf63 between cases
and controls of several cancers
Cancer Accession
number
Array Sample size Log-2 mRNA signal intensity (mean ± SD*) P
Control Case Control Case
Breast cancer GSE42568 HG-U133_Plus_2 17 104 6.36 ± 0.54 7.57 ± 0.78 <0.001
GSE15852 HG-U133A 43 43 9.49 ± 0.18 9.74 ± 0.21 <0.001
Lung cancer E-MEXP-231 HG-U133A 9 49 7.83 ± 0.40 8.62 ± 0.65 0.001
GSE19804 HG-U133_Plus_2 60 60 8.13 ± 0.73 8.41 ± 0.78 0.046
Prostate cancer GSE6956 HG-U133A_2 20 69 9.44 ± 1.11 10.46 ± 0.36 <0.001
GSE6919 HG_U95Av2 81 65 4.62 ± 0.24 4.67 ± 0.23 0.040
Hepatocellular carcinoma GSE14323 HG-U133A_2 19 38 6.95 ± 0.46 7.82 ± 0.53 <0.001
GSE6764 HG-U133_Plus_2 10 62 7.57 ± 0.81 8.45 ± 0.54 <0.001
*SD: standard deviation
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to their IHC scores: 44 (24.2 %) tumors expressing
C1orf63 [C1orf63 (+) group] and 138 (75.8 %) tumors
lacking C1orf63 expression [C1orf63 (−) group]. As
shown in Table 1, no significant correlations were
found between the expression of C1orf63 and the clini-
copathological features collected in this study, includ-
ing age, depth of invasion, lymph node metastasis and
TNM stage. C1orf63 IHC score were also not
associated to the expression of known breast cancer
biomarkers including ER, PR or HER-2.
Impact of C1orf63 expression on OS of breast cancer
patients
To examine whether the expression status of C1orf63 has
any prognostic value for breast cancer, univariate and
multivariate analyses using the Kaplan-Meier method and
Cox regression were carried out. As shown in Table 5, of
the 182 patients breast cancer, the OS rate in the C1orf63
(+) group was higher than that in the C1orf63 (−) group
(3-year OS rates: 83.3 % vs 76.9 %; 5-year OS rates: 73.5 %
vs. 64.9 %), but no significant difference was seen between
these two groups (Log Rank P = 0.145, Fig. 3a), consistent
with the result of univariate Cox regression (Table 6 left).
KM Plotter tool was used to further assess the relationship
between the mRNA expression of C1orf63 and RFS/OS of
breast cancer patients. As shown in Fig. 3c and Fig. 3d, high
expression of C1orf63 predicted a longer RFS and OS in
Fig. 1 C1orf63 expression in cases and controls of several cancers .a IHC detected strong staining of C1orf63 in breast tumors (i, original
magnification 400×), moderate staining of C1orf63 in breast tumors (ii, 400×), weak staining of C1orf63 in breast tumors (iii, 400×) and absent
staining of C1orf63 in adjacent normal tissues (iv, 400×); b C1orf63 mRNA expression was significantly higher in cases than that in controls of
several cancer, namely breast cancer (i, GSE15852; ii, GSE42568), lung cancer (iii, E-MEXP-231; iv, GSE19804), prostate cancer (v, GSE6956; vi,
GSE6919) and hepatocellular carcinoma (vii, GSE14323; viii, GSE6764). P values were derived from student t-test
Table 4 C1orf63 scores detected by IHC in breast tumors and
the adjacent normal tissues. 12 pairs of breast tumors and
corresponding adjacent normal tissues were collected. The
difference of C1orf63 expression between tumors and adjacent
normal tissues were detected by Wilcoxon test
C1orf63 scores (n = 8)
0 1 ~ 4 5 ~ 8
Tumors 0 5 7
Adjacent non-cancerous tissues 4 8 0
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breast cancer patients (P = 0.007; P < 0.001). The dis-
cordance between these two analyses suggests that the
sample size of current IHC study (182 patients) may
not be powerful enough to predict the outcome of the
whole cohort. Since breast cancer is a heterogeneous
disease with defined subtypes, we correlated IHC score
of C1orf63 to the OS in individual subgroups, namely
luminal (Fig. 4A), HER-2 enriched (Fig. 4B), and triple
negative breast cancer patients (Fig. 4C), and no sig-
nificant correlation was found. For the 182 breast can-
cer patients, log rank test also demonstrated that,
depth of invasion (P < 0.001), lymph node metastasis
(P < 0.001), advanced TNM stage (P < 0.001) and negative
PR (P = 0.036), positive HER-2 (P = 0.028) were poor prog-
nostic factors for OS. Patients with elder age (P = 0.074)
or negative ER status (P = 0.242) had a shorter overall sur-
vival, but didn’t reach statistical significance (Table 5),
which was consistent with the result of univariate Cox
regression (Table 6 left).
Table 5 Overall survival related to clinicopathological features and biomarkers. 182 patients with breast cancer were included and
the differences between these OS Rates were tested using the Kaplan–Meier method with log rank test
Variables Patients Events OS rate (%) P
3-year (95 % CI) 5-year (95 % CI) (log-rank)
Age, year
≤ 60 153 45 78.3 (71.6, 85.0) 68.5 (60.1, 76.9) 0.074
> 60 29 13 62.0 (43.2, 80.8) 62.0 (43.2, 80.8)
Depth of invasion
T0 ~ T2 108 22 83.1 (75.7, 90.5) 78.0 (69.2, 86.8) <0.001
T3 ~ T4 72 35 66.3 (55.3, 77.3) 54.3 (41.8, 66.8)
Lymph node metastasis
N0 ~ N1 93 17 87.8 (81.1, 94.5) 84.2 (76.2, 92.2) <0.001
N2 ~ N3 87 40 63.3 (52.7, 73.9) 49.3 (37.0, 61.6)
TNM stage
I ~ II 74 9 92.9 (87.0, 98.8) 88.2 (79.8, 96.6)
III ~ IV 107 49 63.6 (54.2, 73.0) 52.7 (41.9, 63.5) <0.001
ER
Negative 69 25 68.1 (56.7, 79.5) 63.6 (51.4, 75.8) 0.242
Positive 110 31 80.9 (73.5, 88.3) 69.3 (59.1, 79.5)
PR
Negative 107 39 65.8 (56.6, 75.0) 62.7 (52.9, 72.5) 0.036
Positive 72 17 91.3 (84.6, 98.0) 73.7 (60.8, 86.6)
HER2
Negative 108 27 80.9 (73.5, 88.3) 75.3 (65.9, 84.7) 0.028
Positive 70 29 71.1 (60.1, 82.1) 56.2 (43.5, 68.9)
C1orf63
Negative 138 50 73.5 (65.9, 81.1) 64.9 (56.1, 73.7) 0.145
Positive 44 8 83.3 (71.9. 94.7) 76.9 (61.0, 92.8)3
Fig. 2 C1orf63 expression detected by Western blot in four human
breast cancer cell lines including MCF-7, MDA-MB-231, SK-BR3, and BT549
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Next, multivariate analysis was performed to evaluate
the implication of parameters including depth of invasion
(T3 ~ T4), lymph node metastasis (N2 ~N3), TNM stage
(III ~ IV), PR negativity and HER-2 negativity on breast
cancer prognosis (Table 6 right). We found that only
TNM stage (HR: 5.75; 95 % CI: 2.76 ~ 12.00; P < 0.001)
and PR (HR: 0.54; 95 % CI: 0.31 ~ 0.96; P =0.035) were
independent prognostic indicators for breast cancer pa-
tients in our study.
Impact of C1orf63 expression on OS of breast cancer
patients with TNM III ~ IV Stages
Given the result of multivariate analysis mentioned above
(Table 6 right), patients were further divided according to
Fig. 3 Kaplan-Meier survival analyses for assessment of the effect of C1orf63 expression on survival (log-rank test). a Effect of C1orf63 expression
tested by IHC on OS in all the breast cancer patients; b Effect of C1orf63 expression tested by IHC on OS in breast cancer patients with advanced
TNM stage (TNM III ~ IV stage); c Effect of C1orf63 mRNA expression on OS of breast cancer patients included in KM plotter; d Effect of C1orf63
mRNA expression on RFS of breast cancer patients included in KM plotter
Table 6 Cox proportional hazard regression model analysis of OS in patients with breast cancer. 182 patients with breast cancer
were included and the Cox regression analysis was used to study the effects of C1orf63 expression on overall survival (OS). HR,
hazard ratio; 95 % CI: 95 % Confidence Interval
Variables Univariate analysis Multivariate analysis
HR (95 % CI)* P HR (95 % CI)* P
Age, year 1.74 (0.94, 3.23) 0.079
Depth of invasion 2.71 (1.58, 4.63) <0.001
Lymph node metastasis 3.81 (2.13, 6.84) <0.001
TNM stage 6.03 (2.91, 12.49) <0.001 5.75 (2.76, 12.00) <0.001
ER 0.73 (0.43, 1.24) 0.245
PR 0.55 (0.31, 0.97) 0.040 0.54 (0.31, 0.96) 0.035
HER2 1.78 (1.05, 3.01) 0.031
C1orf63 0.58 (0.27, 1.22) 0.152
*HR, hazard ratio; 95 % CI: 95 % Confidence Interval
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either TNM stage or PR levels, in order to analyze the im-
pact of Clorf63 expression on OS in patients with different
TNM stages or PR status. As shown in Table 7, tumors
from 27 of 107 patients (25.2 %) with TNM III ~ IV stages
expressed C1orf63, whereas tumors from the remaining
80 patients (74.8 %) lacked C1orf63 expression. Kaplan-
Meier analysis revealed that patients in TNM III ~ IV
stages with C1orf63 (+) tended to have a better prognosis
than those without C1orf63 expression (3-year OS: 80.0 %
vs. 58.0 %; 5-year OS: 72.7 % vs. 46.2 %; P = 0.036, Fig. 3B).
In contrast, C1orf63 could not predict OS in patients with
TNM early stage (TNM I ~ II stages, P = 0.432), or pa-
tients with PR negativity (P = 0.906) or PR positivity (P =
0.106) expression.
The relationship of C1orf63 expression with clinico-
pathological factors in patients with TNM III ~ IV stages
was further evaluated using Cox regression. As shown in
Table 8 left, the univariate analysis revealed that the
C1orf63 (+) group tended to have a better prognosis
than the C1orf63 (−) group (HR = 0.41; 95 % CI: 0.18 ~
0.98; P = 0.044). Positive PR was also shown as a good
prognosis factor for patients in TNM III ~ IV stages (HR
= 0.52; 95 % CI: 0.27 ~ 0.97; P = 0.039). However, no sig-
nificant difference was observed regarding other clinico-
pathological features. To examine whether C1orf63 was
an independent prognosis factor for patients with TNM
III ~ IV stages, multivariate analysis was performed. It
demonstrated that both C1orf63 expression (Table 8
right, HR: 0.41; 95 % CI: 0.17 ~ 0.97; P = 0.042) and PR
(HR: 0.51; 95 % CI: 0.27 ~ 0.95; P = 0.035) were inde-
pendent prognostic factors for patients in this subgroup.
Association between C1orf63 and CDK10 in breast
cancers
CDK10 has been shown to play a role in cellular pro-
gression as well as a known prognostic factor predicting
better outcome for breast cancers. Given the suggested
role of C1orf63 on cell cycle exit [8], and its capability to
Fig. 4 Kaplan-Meier survival analyses for assessment of the effect of C1orf63 expression in three different subtypes of breast cancer (log-rank test).
Survival analyses of C1orf63 expression separately in luminal breast cancer(a), HER-2 enriched breast cancer (b), and triple negative breast
cancer (c)
Table 7 Impact of C1orf63 expression on OS in different groups of breast cancer patients. 182 patients were divided according to
either TNM stage or PR expression. There were 74 patients with TNM I ~ II stages, 107 patients with TNM III ~ IV stages, 74 patients
with PR positive expression and 107 patients with PR negative expression. The differences of OS rates were tested using the Kaplan–
Meier method with log rank test
Group C1orf63
expression
Patients Events OS rate (%)b P
(log-
rank)
3-year (95 % CI)c 5-year (95 % CI)c
TNM stages (I ~ II) Negative 58 7 94.5 (88.4, 100.0) 83.4 (71.6, 95.2) 0.432
Positive 16 2 87.5 (71.2, 100.0) 87.5 (71.2, 100.0)
TNM stages (III ~ IV) Negative 80 43 58.0 (46.8, 69.2) 46.2 (33.9, 58.5) 0.036
Positive 27 6 80.0 (64.3, 95.7) 72.7 (53.1, 92.3)
PR positive Negative 50 16 87.2 (77.6, 96.8) 70.0 (55.5, 84.5) 0.106
Positive 22 1 100a 83.3 (53.5, 100.0)
PR negative Negative 85 32 65.8 (55.4, 76.2) 62.1 (51.1, 73.1) 0.906
Positive 22 7 65.0 (44.0, 86.0) 65.0 (44.0, 86.0)
a No patients died before the first three years, and the OS was 100 % while the 95 % CI were failed to calculate; bOS rate: Overall survival rate; c95 % CI: 95 %
Confidence Interval
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predict better prognosis for breast cancers (Fig. 3B and
Table 8), we thus examined the relationship between
C1orf63 and CDK10. We firstly took advantage of four
publicly available microarray datasets, each including a
cohort of patients with breast cancer, to evaluate
whether mRNA expression of C1orf63 could be related
to that of CDK10. As shown in Fig. 5B, for mRNA ex-
pression, C1orf63 was positively correlated with CDK10,
and the RNA-seq dataset also displayed a significant cor-
relation between these two genes (r = 0.521, P < 0.001;
Table 2). Further, CDK10 protein expression was exam-
ined by IHC. As shown in Fig. 5Ai, CDK10 primarily
expressed in the nucleus and the relationship between
the IHC scores of CDK 10 and C1orf63 was consistent
with that of their mRNA expressions, which demon-
strated that C1orf63 expression was positively correlated
with CDK10 (rs = 0.391; P < 0.001).
Discussion
Aberrations of chromosome 1 are one of the most fre-
quently detected alterations in a variety of cancers
[28–32]. There are numerous putative candidate onco-
genes located on chromosome 1, e.g., NEGR1 (1p31.1),
JTB (1q21), CKS1B (1q21.2), CHD1L (1q12), SHC1
(1q21) and KIF14 (1q32.1) [33–35]. Besides, 1p36 deletion
has been reported to be associated with carcinogenesis,
and contain genes such as CHD5 (1p36.31), CAMTA1
(1p36.31-p36.23), KIF1B (1p36.22), and CASZ1 (1p36.22).
This specific location suggests C1orf63 might be related
to initiation and development of cancer. However, the
function of C1orf63 has been rarely described. It is dem-
onstrated that C1orf63 protein is interacted with CLK3
(CDC-like kinase 3) and CLK2 (CDC-like kinase 2) pro-
tein [36], both of which are involved in protein phosphor-
ylation and regulation of RNA splicing. It was stated that
AKT activation controls cell survival to ionizing radiation
by phosphorylating CLK2 [37]. As a CLK2-interacting
protein, C1orf63 might participate in these processes.
Additionally, an association between a nonsynonymous
SNP (rs1043879) in C1orf63 and ESR (erythrocyte sedi-
mentation rate), which is a marker of several serious
disease such as infection, autoimmune disorder, and
malignancy [38], was revealed by a genome-wide associ-
ation study with unclear biological significance. However,
all the speculations about C1orf63 still need further study.
Current study is the first to focus on the implication of
C1orf63 in breast cancers.
The genes with abnormal expression hold important
clinical implications as prognostic markers and/or targets
for cancer therapy. According to our results, C1orf63
seems to have dual functions. The tumor-promoting func-
tion of C1orf63 in the initialization of breast cancer was
suggested not only by the higher IHC score of C1orf63 in
breast tumors when compared to adjacent non-cancerous
tissues, also by the higher mRNA expression of C1orf63 in
breast tumor vs. normal controls through analyzing sev-
eral breast cancer gene expression datasets. More import-
antly, the tumor- promoting function of C1orf63 might
not be limited to breast cancer, because gene expression
dataset analysis showed that C1orf63 expression was also
elevated in several other cancer types, including lung,
prostate and hepatocellular carcinoma. Current study also
indicated that the tumor-promoting function of C1orf63
might not involve ER, PR or HER-2, as no significant cor-
relation was observed between the expression of C1orf63
and these biomarkers in either breast cancer tissues or cell
lines. KM Plotter analysis of breast cancer patients showed
that elevated mRNA expression of C1orf63 is significantly
correlated with both longer RFS (P < 0.001) and betetr OS
(P = 0.007), suggested a tumor suppression function of
C1orf63. Most probably limited by the sample size of
current IHC study, the C1orf63 IHC score failed to correl-
ate with OS of all the breast cancer patients, but is capable
of predicting a better prognosis for breast cancer patients
in TNM III ~ IV stages, strongly indicating that C1orf63
could also act as a tumor suppressor, especially in the ad-
vanced stage of breast cancer. Until now, the relationship
of C1orf63 with cancer remains largely unknown. Pils et
al. [39] demonstrated that C1orf63 mRNA was differently
expressed between epithelial ovarian cancer patients and
controls, but the evidence is still limited. We provided the
first evidence for the implication of C1orf63 in breast can-
cer tumorigenesis and progression, and demonstrated that
the function of C1orf63 was complicated.
C1orf63 has been suggested to function in typical
tumor initiation event as cell cycle exit and maintenance
of quiescent state of cells [8]. Many chemotherapeutical
drugs such as Paclitaxel and 5-FU elicit their anti-tumor
activities through forcing cancer cells staying quiescently
[40, 41]. Whether C1orf63 could enhance the efficacy of
therapeutical drugs via keeping cells in a quiescent state
Table 8 Cox regression analysis of breast cancer patients with
TNM III ~ IV stages. 107 breast cancer patients with TNM III ~ IV
stages were included and the Cox regression analysis was used
to study the effects of C1orf63 expression on overall survival
(OS). HR, hazard ratio; 95 % CI: 95 % Confidence Interval
Variables Univariate analysis Multivariate analysis
HR (95 % CI)* P HR (95 % CI)* P
Age, year 1.50 (0.76, 2.95) 0.239
Depth of invasion 1.37 (0.74, 2.52) 0.32
Lymph node metastasis 1.26 (0.59, 2.72) 0.549
ER 0.69 (0.39, 1.24) 0.218
PR 0.52 (0.27, 0.97) 0.039 0.51 (0.27, 0.95) 0.035
HER2 1.62 (0.91, 2.90) 0.102
C1orf63 0.41 (0.18, 0.98) 0.044 0.41 (0.17, 0.97) 0.042
*HR, hazard ratio; 95 % CI: 95 % Confidence Interval
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and thus predict a better outcome of cancer patients is
unknown but a potential mechanism. Similar to
C1orf63, the dual functions have been observed for
many proteins, such as SRSF1 (serine/arginine-rich spli-
cing factor 1). SRSF1 is a proto-oncogene that is overex-
pressed in many different cancers. However, increased
SRSF1 expression in primary human fibroblasts could
ultimately triggers oncogene-induced senescence via sta-
bilizing p53 [42]. Even so, the mechanism under the
seemingly reversible action of C1orf63 still needs further
study.
Recent studies have shown that CDK10 is a potential
tumor suppressor in breast cancers, and CDK10/Ets2/c-
RAF signaling has been demonstrated as an important de-
terminant of breast cancer resistance to endocrine therapy
[43]. Since C1orf63 might be involved in cell cycle exit, we
thus correlated the IHC score of CDK10 to that of
C1orf63 in the same cohort, and detected that higher
C1orf63 expression was positively associated with en-
hanced CDK10 expression, suggesting that C1orf63 prob-
ably function in a mechanism involving CDK10. Further
research is needed to detect the underlying mechanism.
Conclusions
C1orf63 expression was supposed to be an early event of
breast cancer oncogensis. It served as a favourable and
Fig. 5 C1orf63 expression in human breast tissues and its correlation with CDK10. IHC detected staining of CDK10 in tumors (a, i) and absent
staining for CDK10 in tumors (a, ii); CDK10 was significantly correlated with C1orf63 in patients with breast cancer from datasets E-GEOD-4922 (b,
i), E-GEOD-5847 (b, ii), E-GEOD-23988 (b, iii) and E-TABM-158 (b, iv). The Y-axis and X-axis respectively represented the mRNA expression of CDK10
and C1orf63 on the log-2 scale
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independent prognostic marker for patients with breast
cancer in TNM III ~ IV stages, suggesting C1orf63 might
elicit two different functions involved in the oncogenesis
and progression of breast cancer. Moreover, its positive
correlation with CDK10 suggests that C1orf63 might be
involved in cell cycle progression. Further work are war-
ranted to better understand the potential function of
C1orf63 in cancer pathogenesis.
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